Office of the CEO

The Office of the Chief Executive Officer (CEO) of the Food and Drugs Authority (FDA) Ghana plays a pivotal role in safeguarding public health through stringent regulatory oversight. Recent developments, including the appointment of Professor Kwabena Frimpong-Manso Opuni as the Acting CEO, underscore the dynamic nature of this critical office. This article delves into the statutory framework governing the FDA CEO's powers and responsibilities, primarily under the Public Health Act, 2012 (Act 851). It examines the legal implications of such leadership transitions on the Authority's operational management, strategic direction, and its overarching mandate to ensure the safety, quality, and efficacy of regulated products in Ghana, providing essential insights for legal practitioners navigating the regulatory landscape.

A recent development saw Professor Kwabena Frimpong-Manso Opuni assume the role of Acting Chief Executive Officer of the FDA, effective July 14, 2025, succeeding Dr. Delese Mimi Darko, who transitioned to lead the African Medicines Agency (AMA). This change at the helm of Ghana's primary regulatory body for food and drugs necessitates a closer examination of the legal underpinnings of the CEO's office. This article aims to provide legal professionals with a comprehensive understanding of the statutory framework that defines the FDA CEO's authority, responsibilities, and the broader implications of such appointments on regulatory practice and compliance within Ghana.

Under this legislative framework, the FDA is mandated to ensure the safety, quality, and efficacy of human and veterinary drugs, food, biological products, cosmetics, medical devices, household chemical substances, and to oversee clinical trials. The Authority's functions include establishing and enforcing standards, monitoring compliance, advising the Minister of Health on consumer protection measures, and approving the initiation and conduct of clinical trials. The Chief Executive Officer is statutorily recognized as a public officer, appointed by the President in accordance with Article 195 of the Constitution, and is entrusted with the day-to-day administration of the Authority's affairs.

The CEO's role is crucial in driving the FDA's objectives, which include regulatory oversight, public awareness campaigns, and quality assurance through rigorous inspection and testing. The Authority's ability to enforce standards, issue licenses, register products, and conduct market surveillance hinges on the effective leadership and decision-making emanating from the CEO's office. Any directives or policy statements issued by the CEO carry the full weight of the Authority's statutory mandate, impacting all regulated entities and practitioners within the Ghanaian health and food sectors. The transition in leadership, therefore, while maintaining operational continuity, may also herald new strategic emphases or approaches to regulatory enforcement and public engagement.

For attorneys advising clients in the food, pharmaceutical, and related industries, it is crucial to monitor the FDA's official communications, particularly those emanating from the CEO's office, for any updated guidelines, enforcement priorities, or policy directions. Understanding the legal framework underpinning the CEO's authority, as enshrined in the Public Health Act, 2012 (Act 851), is paramount for ensuring client compliance and effectively navigating the evolving regulatory landscape in Ghana. The continuity of strong leadership at the FDA is vital for maintaining public trust and fostering a safe and healthy market for all Ghanaians.